Pfizer opts for EVOscreen system
The latest drug development site to accept the EVOscreen Mark II uHTS system is Pfizer's installation at Groton, CT, US.
EVOscreen from EVOTEC BioSystems is a system designed for ultra high throughput screening (uHTS) for identifying novel drug candidates. It combines miniaturisation, automation and EVOTEC's proprietary single molecule detection technology to yield a potential throughput of 100,000 tests per day.
The system has previously been used by both Novartis and Pfizer UK.